<DOC>
	<DOCNO>NCT01002690</DOCNO>
	<brief_summary>The study part research programme mechanism asthmatic airway obstruction , focus role lipid mediator prostaglandin . To end effect non-steroidal anti-inflammatory drug , selective COX-2 inhibitor etoricoxib , evaluate allergen challenge set twelve subject intermittent allergic asthma . Active treatment 10 13 day compare identical study period treatment cross-over , randomise design . Rising dose allergen challenge perform three occasion assess possible change airways responsiveness . Sampling blood , urine , saliva sputum do allow analysis production prostaglandins lipid mediator , efficacy COX-2 inhibition well regulation immune cell . It hypothesize inhibition COX-2 virtue inhibition bronchoprotective prostaglandin E2 lead slightly exaggerated airway response allergen exposure .</brief_summary>
	<brief_title>COX-2 Inhibition Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Female male age 18 55 year inclusive A history asthma least 6 month least one follow : response standard asthma treatment episodic wheeze change lung function short period time A positive methacholine challenge test evidence PD20 ≤7256 µg cumulate dose within 8 week prior screen screen visit . Stable intermittent asthma , use bronchodilator therapy need last 4 week . FEV1 ≥ 75 % predict . A positive skin prick test pollen ( grass , birch , mugwort ) animal dander ( dog , cat ) Known suspect hypersensitivity coxibs Any significant respiratory disease asthma Respiratory tract infection within 4 week inclusion . Any significant disease disorder , opinion investigator , may put patient risk participation study . In particular previous present history cardiovascular disease , ie myocardial infarction , stroke , severe hypertension , leave ventricular heart failure and/or pulmonary hypertension strict exclusion criterion . Current former smoker within last year smoke history &gt; 4 packyears Pregnancy/breastfeeding Use : inhaled glucocorticosteroid treatment use oral corticosteroid last 8 week prior inclusion study . inhale longacting oral beta2agonists , anticholinergic bronchodilator , cromones , antihistamine , theophylline antileukotrienes within 2 week screen study . paracetamol , NSAIDs antiinflammatory drug last 2 week prior inclusion study . need regular drug treatment may interfere study outcome . BMI &gt; 30 kg/m2 . Use betablocking agent Any nonasthmarelated , clinically significant abnormal find physical and/or vital sign , and/or hematology blood chemistry test visit 1 , opinion investigator , may put patient risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergen challenge</keyword>
	<keyword>Airway responsiveness</keyword>
	<keyword>Prostaglandins</keyword>
	<keyword>Eicosanoids</keyword>
</DOC>